Drugs / Donor CD3+
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05806749 Background | Jul 2023 → Aug 2028 expected | chronic transplant rejection, end stage renal failure | University of California, Los Angeles | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor CD3+ | “Donor CD34+, CD3+. and belumosudil” NCT05806749 ↗ |